These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24293573)

  • 1. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
    Shafferman A; Fontaine KR; Cron RQ; Beukelman T
    J Rheumatol; 2014 Jan; 41(1):113-8. PubMed ID: 24293573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.
    Uettwiller F; Perlbarg J; Pinto G; Bader-Meunier B; Mouy R; Compeyrot-Lacassagne S; Melki I; Wouters C; Prieur AM; Landais P; Polak M; Quartier P
    J Rheumatol; 2014 Jan; 41(1):128-35. PubMed ID: 24293576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan.
    Hsin YC; Zhuang LZ; Yeh KW; Chang CW; Horng JT; Huang JL
    PLoS One; 2015; 10(6):e0128768. PubMed ID: 26047099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.
    Beukelman T; Haynes K; Curtis JR; Xie F; Chen L; Bemrich-Stolz CJ; Delzell E; Saag KG; Solomon DH; Lewis JD;
    Arthritis Rheum; 2012 Apr; 64(4):1263-71. PubMed ID: 22328538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.
    Donnithorne KJ; Cron RQ; Beukelman T
    J Rheumatol; 2011 Dec; 38(12):2675-81. PubMed ID: 22089470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year followup study on clinical findings and changes in magnetic resonance imaging-based disease activity scores in juvenile idiopathic arthritis.
    Hemke R; van Veenendaal M; van den Berg JM; Dolman KM; van Rossum MA; Maas M; Kuijpers TW
    J Rheumatol; 2014 Jan; 41(1):119-27. PubMed ID: 24293575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.
    Gremese E; Bernardi S; Bonazza S; Nowik M; Peluso G; Massara A; Tolusso B; Messuti L; Miceli MC; Zoli A; Trotta F; Govoni M; Ferraccioli G
    Rheumatology (Oxford); 2014 May; 53(5):875-81. PubMed ID: 24407233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Hyrich KL; Davies R; Lunt M; Southwood TR;
    Rheumatology (Oxford); 2015 Jul; 54(7):1279-85. PubMed ID: 25638806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
    Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
    Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
    Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B
    Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
    Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
    Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
    Russo RA; Katsicas MM
    J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.